Section Arrow
SER.NYSE-M
- Serina Therapeutics
(Financial Status)
Quotes are at least 15-min delayed:2026/07/22 18:43 EDT
After Hours
Last
 2.21
+0.04 (+1.84%)
Bid
2.15
Ask
2.28
High 2.28 
Low 2.16 
Volume 328 
Regular Hours (Closed)
Last
 2.17
+0.08 (+3.83%)
Day High 
2.281 
Prev. Close
2.09 
1-M High
2.2799 
Volume 
68.04K 
Bid
2.15
Ask
2.28
Day Low
2.1 
Open
2.13 
1-M Low
1.7101 
Market Cap 
31.34M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 2.08 
20-SMA
50-SMA 1.88 
52-W High 7.92 
52-W Low 1.22 
Exchange NYSE-M 
Valuation Estimation
EPS (Current/Estimated)
-2.00/-1.79
Enterprise Value
34.49M
Balance Sheet
Book Value Per Share
0.85
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
LABTLakewood-Amedex Biotherapeutics Inc3.41+1.55+83.33%-- 
After Hours 3.33 -0.08 -2.35%
KAPAKairos Pharma Ltd.0.3127-0.0453-12.65%-- 
After Hours 0.293 -0.0197 -6.30%
JUNSJupiter Neurosciences Inc0.1746+0.0049+2.89%-- 
After Hours 0.1677 -0.0069 -3.95%
GOSSGossamer Bio0.1446-0.0102-6.59%-- 
After Hours 0.1439 -0.0007 -0.48%
RXRXRecursion Pharmaceuticals2.98-0.1-3.25%-- 
After Hours 2.9901 +0.0101 +0.34%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers.The company has one reportable segment relating to the research and development of its POZ platform. The segment derives its revenues from Grant revenue. Its main product candidate, SER-252 for advanced Parkinson's disease, is anticipated to enter clinical trials.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.